Zurabio
  • About Us
  • Pipeline
    • Alopecia Areata
    • Type 1 Diabetes
    • Other Indications
  • Science
    • ZB-168
    • IL7 & TLSP pathways
    • Scientific publications
  • News
    • Press releases
    • In the news
    • Events & presentations
  • Contact
Select Page
JATT and Zura Bio to Create NYSE Listed Biotechnology Company

JATT and Zura Bio to Create NYSE Listed Biotechnology Company

by Ashle Whittle | Jun 17, 2022 | In The News, Press Releases

JATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology Company Company advancing ZB-168, an anti-IL7Ra monoclonal antibody, originally developed by Pfizer Inc., in multiple phase 2 clinical...

Recent Posts

  • JATT and Zura Bio to Create NYSE Listed Biotechnology Company

Archive

  • June 2022

Info@zurabio.com

About Us
Science
Contact
Privacy Policy
 

Connect

Copyright © 2022 Zurabio

All rights reserved